PHILADELPHIA, April 14 /PRNewswire-FirstCall/ -- eResearchTechnology,
Inc. (eRT), (Nasdaq: ERES), and nSpire Health, Inc. announced today their
alliance to provide integrated Cardiac Safety and Pulmonary Core Lab
Services to clinical researchers worldwide.
eResearchTechnology is a leading provider of centralized
electrocardiographic (ECG), eClinical technology, ePRO, and other services
to the pharmaceutical, biotechnology, medical device, and related
industries. nSpire Health is a leading provider of respiratory clinical
trials services, including Cardiopulmonary Exercise Testing, High
Definition Pulmonary Diagnostics Systems, Spirometry, and Home Monitoring.
Under the agreement, eRT and nSpire will deliver a combined solution to
meet the increased demand for cardio-pulmonary safety and efficacy services
during clinical trials, in part caused by an increased interest in using
inhaled therapeutics. The partnership will offer integrated services from
project planning and set-up through study conduct, management, and data
delivery for primary and secondary Cardiac and Respiratory clinical trial
endpoints. nSpire Health will provide eSP(TM) Core Lab Data Management
software, QA services, HDpft(TM), KoKo(R), PiKo(R), and PiKoLogic(TM)
(electronic Diary) respiratory diagnostic measuring instruments. eRT will
perform digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT 2.0 workflow-enabled
data management system.
"This alliance addresses a growing need in clinical research to offer
comprehensive, best in class services in these two closely related areas of
clinical study," said Michael McKelvey, President and CEO of eRT. "While
many sponsors recognize and source each company for its respective area of
expertise, customers increasingly seek consolidation and streamlining in
all phases of a clinical trial. eRT and nSpire Health approach the market
in the same way -- focusing on scientific excellence, providing a quality
product, and client satisfaction. We are both metrics driven and process
oriented to ensure on-time, on-budget, reliable data delivery on a global
scale."
"Clinical trial sponsors have a strategic need to deliver accurate,
cost- effective results in less time. They need therapeutic specialists
that they can trust. This partnership leverages the world's most advanced
Cardio- Respiratory specific technologies and data management services from
each company into one unified source, reducing costs and accelerating time
to market for emerging inhaled therapeutic trials," commented Michael S.
Sims, President and CEO of nSpire Health, Inc.
About nSpire Health
nSpire Health develops and manufactures respiratory care products and
provides related services in over 100 countries. The company is focused on
cardiopulmonary diagnostics, respiratory core lab services, and disease
management solutions designed to improve health care productivity while
increasing the overall quality of patient care. nSpire Health is the
exclusive provider of PiKo(R) home health monitors and HDpft(TM) systems,
the most accurate and precise pulmonary function testing systems worldwide.
About eRT
Based in Philadelphia, Pa, eResearchTechnology, Inc. (http://www.eRT.com) is a
provider of technology and services to the pharmaceutical, biotechnology
and medical device industries on a global basis. The company is a market
leader in providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services to
streamline the clinical trials process by enabling its customers to
automate the collection, analysis and distribution of clinical data in all
phases of clinical development.
Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements, including, but not limited to, 2008 financial
guidance, involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of
projects, and internal issues at the sponsoring client, integration of
acquisitions, competitive factors, technological development, and market
demand. As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential factors
that could affect the Company's financial results can be found in the
Company's Reports on Form 10-K and 10-Q filed with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.
See Also
- Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
- Fluoride-Induced Spots on Teeth Harm Kids' Self-Esteem, says Dental Journal
- EPA Reaches Agreement With American Energy on Clean-Air Violations
- Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
Via: Healthcare
0 коментарі:
Post a Comment